Co-administration of MDR1 and BCRP or EGFR/PI3K inhibitors overcomes lenvatinib resistance in hepatocellular carcinoma

Lenvatinib is the first-line treatment for hepatocellular carcinoma (HCC), the most common type of primary liver cancer; however, some patients become refractory to lenvatinib. The underlying mechanism of lenvatinib resistance (LR) in patients with advanced HCC remains unclear. We focused on explori...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Dawei, Liu, Juan, Wang, Yunfang, Dong, Jiahong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496645/
https://www.ncbi.nlm.nih.gov/pubmed/36158676
http://dx.doi.org/10.3389/fonc.2022.944537

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496645/
https://www.ncbi.nlm.nih.gov/pubmed/36158676
http://dx.doi.org/10.3389/fonc.2022.944537

Ejemplares similares